Navigation Links
CEL-SCI Takes Delivery of New Manufacturing Facility
Date:10/9/2008

t will increase their survival. Head and neck cancer is one of the world's biggest cancers affecting about 650,000 people per annum worldwide.

About CEL-SCI's Phase III Cancer Drug Multikine:

In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007. In the summer of 2007 CEL-SCI started construction of the manufacturing facility to produce Multikine for the Phase III trial and subsequent sale following approval.

Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received chemotherapy and/or radiation therapy, which can limit their effectiveness.

CEL-SCI has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense. Most recently CEL-SCI announced that its newly discovered rheumatoid arthritis vaccine showed excellent results in animal tests.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. CEL-SCI to Present at the Noble Financial Conference
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
5. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
6. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
7. First European IGRT School Takes Place for Radiotherapy Practitioners in UK
8. Ground-Breaking Conference Takes on Abortion
9. White Paper Advises Pharma Manufacturers on How to Select an Aseptic Fill/Finish Contractor, Avoid the Most Common Mistakes
10. Ganeden Biotech Takes Sustenex(TM) National with GanedenBC30 Probiotic
11. Tepper School Team Takes Top Honors at Global Moot Corp(R) Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Yuma Regional Cancer ... complementary therapies brings comprehensive cancer care to Yuma, ... Regional Cancer Center has officially opened. A Mayo ... includes services such as open, semi-private and private ... Cancer Society Resource Center, hematology, rehabilitation center, a ...
(Date:7/30/2014)... DIEGO , July 30, 2014   Epic ... designs and develops novel diagnostics to personalize and advance ... appoint of Gregory T. Lucier as chairman ... chairman and CEO of Life Technologies (formerly Invitrogen). Mr. ... as Epic commercializes its circulating rare cell analysis platform ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Connecticut Center ... organization based in East Hartford, Conn., was awarded a ... II of a project that will determine the feasibility ... rural north-central Connecticut. USDA Rural Development provided $53,000 for ... for the second phase of the feasibility study in ...
(Date:7/30/2014)... LayerBio, Inc., an MIT spinoff developing ... round of seed financing from friends and family investors. ... develop a novel sustained-release product for ophthalmology. , "We ... their commitment to this important work," said Dr. Ken ... of many areas in which innovations in drug delivery ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3
... Watson,Pharmaceuticals, Inc. (NYSE: WPI ), a ... received final approval from the,United States (U.S.) Food ... Application (ANDA) for albuterol sulfate inhalation solution in,the ... been awarded 180,days of marketing exclusivity for being ...
... Huge Opportunity Exists for Development of More Effective Therapies ... Report from Decision Resources, WALTHAM, Mass., Sept. 26 ... advisory firms for pharmaceutical and,healthcare issues, finds that the ... Genesys, will be the key factor driving the,pancreatic cancer ...
... PALO ALTO, Calif., Sept. 26 Jazz,Pharmaceuticals, Inc. ... Cozadd, the,company,s Executive Chairman, will provide a corporate ... New York, NY on October 8,2007 at 8:00 ... the presentation may be accessed by visiting the,Investors ...
Cached Biology Technology:Watson Receives FDA Approval for Generic Accuneb(R) 2Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016 2
(Date:7/30/2014)... Red Queen in Lewis Carroll,s Through the Looking ... National University of Singapore improved a 35-year-old ecology ... decades to millions of years. , The new ... incorporates the "Red Queen Effect," an evolutionary hypothesis ... which suggests that organisms must constantly increase their ...
(Date:7/30/2014)... studying the potential effects of climate change on ... on the wrong factors, according to a new ... Conservation Society, University of Queensland, and other organizations. ... science is missing the point when it comes ... of climate change scientists focus on the "direct" ...
(Date:7/30/2014)... group of researchers from the University of Helsinki and ... to reproduce in mice morphological changes which have taken ... modifications in the embryonic development of mice teeth, induced ... are very similar to those observed in the fossil ... of years ago. , To modify the development ...
Breaking Biology News(10 mins):Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3Conservation scientists asking wrong questions on climate change impacts on wildlife 2Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2
... 2007) Where does the benefit lie in an afternoon nap" ... taking a snooze" Researchers in the United Kingdom have ... where beneficial cardiovascular changes take place. This finding ... Function During the Onset Period of Daytime Sleep: Comparison to ...
... illicit drug worldwide and the illegal drug most frequently ... EU countries during the 1990s, in particular among young ... 15- to 24-year-olds, with lifetime prevalence ranging for most ... has been a new surge in the level of ...
... CA, October 13, 2007Today at the Prostate Cancer Foundations ... how eating common foods such as tomatoes and fish, ... high temperatures may help prevent prostate cancer, and help ... in six men will be diagnosed with prostate cancer ...
Cached Biology News:Expecting an afternoon nap can reduce blood pressure 2Expecting an afternoon nap can reduce blood pressure 3The endocannabinoids: Functional roles and therapeutic opportunities 2The endocannabinoids: Functional roles and therapeutic opportunities 3The endocannabinoids: Functional roles and therapeutic opportunities 4Leading researchers to reveal comprehensive dos and don'ts for prostate cancer 2Leading researchers to reveal comprehensive dos and don'ts for prostate cancer 3
Peroxidase Protective Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods....
... Digest Medium (TSB), USP is a highly ... general laboratory use. Due to the inclusion ... medium will support growth of many fastidious ... , Product conforms to United States Pharmacopeia ...
... and endothelial cells-directed transfection reagent ... peptide-conjugated polyethylenimine which allows targeted ... and endothelial cells. Integrins are ... and cell-matrix adhesion processes. Many ...
... is used to predict the ... sequence up to 3,200 bases, ... of primers and GC clamps ... gradient gel electrophoresis (DGGE), constant ...
Biology Products: